Astec LifeSciences · NSE: ASTEC · BSE: 533138
Q1 FY27 results · Apr–Jun 2026
Astec LifeSciences reported revenue from operations of ₹83.56 crore (down 8.3% from Q1 FY26) and net loss of ₹18.71 crore for Q1 FY27 (Apr–Jun 2026), on a consolidated basis.
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 83.56 | 91.08 | −8.3% | 158.62 | −47.3% |
| Other income | 0.73 | 0.51 | +43.6% | 2.63 | −72.4% |
| Total income | 84.29 | 91.59 | −8.0% | 161.26 | −47.7% |
| Profit before tax | (18.74) | (33.02) | Loss narrowed | (7.90) | Loss widened |
| Net profit for the period | (18.71) | (33.03) | Loss narrowed | (7.75) | Loss widened |
| Attributable to shareholders of the company | (18.72) | (33.04) | Loss narrowed | (7.76) | Loss widened |
| EPS, basic (₹) | (8.40) | (16.85) | not comparable | (3.48) | Loss widened |
| Net margin (%) | -22.4 | -36.3 | -4.9 |
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 83.56 | 91.08 | −8.3% | 158.62 | −47.3% |
| Other income | 0.71 | 0.49 | +45.6% | 2.61 | −72.9% |
| Total income | 84.27 | 91.57 | −8.0% | 161.24 | −47.7% |
| Profit before tax | (18.78) | (33.06) | Loss narrowed | (7.94) | Loss widened |
| Net profit for the period | (18.74) | (33.06) | Loss narrowed | (7.78) | Loss widened |
| EPS, basic (₹) | (8.41) | (16.86) | not comparable | (3.49) | Loss widened |
| Net margin (%) | -22.4 | -36.3 | -4.9 |
Consolidated
- Filed with BSE
- 31 Jul 2026, 21:44 IST
- Board meeting
- 31 Jul 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 31 Jul 2026, 21:44 IST
- Board meeting
- 31 Jul 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE